250 related articles for article (PubMed ID: 28045934)
1. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
[TBL] [Abstract][Full Text] [Related]
2. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
3. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
[TBL] [Abstract][Full Text] [Related]
4. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis.
Vesga JF; Lienhardt C; Nsengiyumva P; Campbell JR; Oxlade O; den Boon S; Falzon D; Schwartzman K; Churchyard G; Arinaminpathy N
BMC Med; 2022 May; 20(1):182. PubMed ID: 35581650
[TBL] [Abstract][Full Text] [Related]
5. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
Kendall EA; Azman AS; Cobelens FG; Dowdy DW
PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116
[TBL] [Abstract][Full Text] [Related]
6. Prospects for advancing tuberculosis control efforts through novel therapies.
Salomon JA; Lloyd-Smith JO; Getz WM; Resch S; Sánchez MS; Porco TC; Borgdorff MW
PLoS Med; 2006 Aug; 3(8):e273. PubMed ID: 16866578
[TBL] [Abstract][Full Text] [Related]
7. Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.
Fofana MO; Knight GM; Gomez GB; White RG; Dowdy DW
PLoS One; 2014; 9(5):e96389. PubMed ID: 24816692
[TBL] [Abstract][Full Text] [Related]
8. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
[TBL] [Abstract][Full Text] [Related]
9. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
10. The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.
Arinaminpathy N; Gomez GB; Sachdeva KS; Rao R; Parmar M; Nair SA; Rade K; Kumta S; Hermann D; Hanson C; Chin DP; Dewan P
PLoS One; 2020; 15(3):e0230808. PubMed ID: 32218585
[TBL] [Abstract][Full Text] [Related]
11. Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis.
Denkinger CM; Kampmann B; Ahmed S; Dowdy DW
BMC Infect Dis; 2014 Sep; 14():477. PubMed ID: 25186052
[TBL] [Abstract][Full Text] [Related]
12. Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.
Kendall EA; Schumacher SG; Denkinger CM; Dowdy DW
PLoS Med; 2017 Dec; 14(12):e1002472. PubMed ID: 29240766
[TBL] [Abstract][Full Text] [Related]
13. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
[TBL] [Abstract][Full Text] [Related]
14. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.
Menzies NA; Allwood BW; Dean AS; Dodd PJ; Houben RMGJ; James LP; Knight GM; Meghji J; Nguyen LN; Rachow A; Schumacher SG; Mirzayev F; Cohen T
Nat Commun; 2023 Oct; 14(1):6182. PubMed ID: 37794037
[TBL] [Abstract][Full Text] [Related]
15. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
16. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
[TBL] [Abstract][Full Text] [Related]
17. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.
Kendall EA; Hussain H; Kunkel A; Kubiak RW; Trajman A; Menzies R; Drain PK
BMC Med; 2021 Dec; 19(1):315. PubMed ID: 34903214
[TBL] [Abstract][Full Text] [Related]
19. Six-month therapy for abdominal tuberculosis.
Jullien S; Jain S; Ryan H; Ahuja V
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
